Moleculin Biotech announces 1-for-15 reverse stock split to regain Nasdaq compliance

Moleculin Biotech, Inc.

Reverse split at 1:15 ratio effective March 21, 2024 after market close; trading on split-adjusted basis from March 22.
Outstanding shares reduced from ~33.4M to ~2.2M; authorized shares unchanged at 100M.
Ticker symbol remains "MBRX" but new CUSIP 60855D309; no fractional shares, rounding up.
Reverse split intended to cure minimum bid price deficiency for continued Nasdaq listing.
Proportional adjustments to outstanding stock options, warrants, and equity plan shares.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Moleculin Biotech, Inc.: Reverse stock split of common stock at 1:15 ratio approved by stockholders and board, effective March 21, 2024 (effective 2024-03-21).

Change: charter amendment
Effective: 2024-03-21

Exact text from the filing

The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split will become effective in accordance with the terms of the Amendment at 11:59 p.m. Eastern Time on March 21, 2024

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-008537

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.